Global Stereotactic Body Radiation Therapy (SBRT) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Stereotactic Body Radiation Therapy (SBRT) Market Size

• The global stereotactic body radiation therapy (SBRT) market size was valued at USD 3.8 billion in 2025and is expected to reach USD 8.1 billion by 2033, at a CAGR of 9.8% during the forecast period
• Growth is driven by the increasing prevalence of cancer globally and rising demand for non-invasive, high-precision radiotherapy treatments
• Rising adoption of image-guided and motion-managed radiotherapy techniques is accelerating market expansion

Stereotactic Body Radiation Therapy (SBRT) Market Analysis

• SBRT is a highly precise radiation therapy technique that delivers high-dose radiation to tumors in fewer treatment sessions, minimizing damage to surrounding healthy tissues
• The increasing burden of cancers such as lung, prostate, and liver cancer is significantly driving demand for SBRT solutions due to their efficacy, reduced treatment time, and improved patient outcomes
• North America dominated the SBRT market with the largest revenue share of ~38.2% in 2025, supported by advanced healthcare infrastructure, high adoption of innovative oncology technologies, and strong reimbursement frameworks
• Asia-Pacific is expected to be the fastest-growing region due to expanding healthcare infrastructure, increasing cancer incidence, and growing investments in radiotherapy equipment
• The linear accelerator-based SBRT segment dominated the market with a share of approximately 45.6% in 2025, driven by widespread adoption and cost-effectiveness compared to advanced robotic systems.

Report Scope and Stereotactic Body Radiation Therapy (SBRT) Market Segmentation

Stereotactic Body Radiation Therapy (SBRT) Market Trends

“Rising Adoption of Precision Oncology and Hypofractionated Radiotherapy”

• A significant and accelerating trend in the global stereotactic body radiation therapy (SBRT) market is the growing shift toward precision oncology and hypofractionated treatment approaches, enabling high-dose radiation delivery in fewer sessions while minimizing damage to surrounding healthy tissues.
• For instance, companies such as Varian Medical Systems and Elekta AB are increasingly developing advanced SBRT platforms integrated with real-time imaging, motion tracking, and AI-based treatment planning systems, improving treatment accuracy and efficiency.
• Technological advancements in image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and adaptive radiotherapy are enabling the development of SBRT systems with enhanced targeting precision and improved clinical outcomes.
• The increasing adoption of non-invasive cancer treatment options and outpatient radiotherapy procedures is supporting the demand for SBRT systems that enhance patient convenience and reduce hospitalization time.
• This trend toward high-precision, personalized cancer treatment solutions is reshaping industry expectations for treatment quality, workflow efficiency, and patient safety across oncology centers.
• The demand for advanced SBRT systems with AI integration, real-time tumor tracking, and automation capabilities is growing rapidly across both developed and emerging healthcare markets.
• Increasing adoption of robotic radiosurgery systems and MRI-guided radiotherapy is gaining traction due to rising demand for improved treatment accuracy and better patient outcomes across complex tumor cases.

Stereotactic Body Radiation Therapy (SBRT) Market Dynamics

Driver

“Rising Global Cancer Burden and Demand for Non-Invasive Treatment Solutions”

• The increasing prevalence of cancer globally, particularly lung, prostate, and liver cancers, is a major driver fueling the growth of the stereotactic body radiation therapy (SBRT) market.
• For instance, healthcare systems across regions such as North America and Europe are increasingly adopting advanced radiotherapy technologies to improve cancer treatment outcomes and reduce treatment durations.
• As healthcare providers focus more on improving treatment precision and patient quality of life, SBRT offers advantages such as shorter treatment cycles, reduced side effects, and improved tumor control.
• Furthermore, the growing shift toward minimally invasive and outpatient-based treatment approaches, supported by rising patient awareness and technological advancements, is increasing the adoption of SBRT systems.
• The versatility of SBRT across applications such as lung cancer, prostate cancer, spine tumors, and liver cancer, along with its ability to deliver highly targeted radiation doses, is driving widespread adoption.
• Expanding healthcare infrastructure and rising investments in oncology treatment facilities in emerging economies are further supporting market expansion.
• Government initiatives, cancer screening programs, and funding for advanced radiotherapy equipment are accelerating investments and commercialization of SBRT technologies globally.

Restraint/Challenge

“High Capital Investment and Limited Accessibility in Emerging Regions”

• Challenges related to the high cost of SBRT systems, including linear accelerators, robotic radiosurgery systems, and proton therapy equipment, pose significant barriers to adoption, particularly in cost-sensitive markets.
• For instance, SBRT implementation requires advanced infrastructure, specialized facilities, and skilled professionals, which may not be readily available in developing regions.
• Addressing these challenges through cost optimization, public-private partnerships, and healthcare infrastructure development is critical for enhancing market penetration.
• While demand for advanced cancer treatments is increasing, limited availability of trained radiation oncologists and medical physicists may restrict adoption in certain regions.
• Overcoming these challenges through training programs, automation, and AI-driven treatment planning systems will be essential for long-term market growth.
• Reimbursement limitations and regulatory complexities in some regions can also increase financial burden and affect adoption rates.

Stereotactic Body Radiation Therapy (SBRT) Market Scope

The market is segmented on the basis of technology, application, end user, and component.

• By Technology

On the basis of technology, the global stereotactic body radiation therapy (SBRT) market is segmented into linear accelerator-based SBRT, CyberKnife systems, proton beam therapy, gamma knife, and others. The linear accelerator-based SBRT segment dominated the market with the largest revenue share of approximately 45.6% in 2025, driven by its widespread availability, cost-effectiveness, and strong adoption across hospitals and cancer treatment centers. These systems are widely preferred due to their versatility in treating multiple tumor types, integration with image-guided radiotherapy (IGRT), and compatibility with existing oncology infrastructure. Continuous technological advancements, including improved imaging and treatment planning capabilities, are further strengthening segment dominance globally.

The CyberKnife systems segment is expected to witness the fastest growth during the forecast period, fueled by rising demand for highly precise, robotic radiation delivery systems with real-time tumor tracking capabilities. Increasing adoption in treating complex and inoperable tumors, along with advancements in motion management and automation, is driving segment growth. Additionally, growing preference for non-invasive and outpatient cancer treatment solutions is further accelerating the adoption of CyberKnife systems globally.

• By Application

On the basis of application, the global SBRT market is segmented into lung cancer, prostate cancer, liver cancer, spine tumors, pancreatic cancer, and others. The lung cancer segment dominated the market with the largest revenue share of approximately 34.8% in 2025, driven by the high global prevalence of lung cancer and strong clinical evidence supporting the effectiveness of SBRT in early-stage and inoperable cases. SBRT is widely used in lung cancer treatment due to its ability to deliver high-dose radiation with minimal damage to surrounding tissues, improving patient outcomes and survival rates.

The prostate cancer segment is expected to witness the fastest growth during the forecast period, fueled by increasing adoption of hypofractionated radiotherapy protocols and growing awareness regarding advanced treatment options. The ability of SBRT to reduce treatment duration and improve patient convenience is significantly contributing to segment growth. Additionally, increasing incidence of prostate cancer and advancements in imaging and targeting technologies are further supporting expansion.

• By End User

On the basis of end user, the global SBRT market is segmented into hospitals, cancer treatment centers, and ambulatory surgical centers. The hospitals segment dominated the market with the largest revenue share in 2025, driven by the availability of advanced healthcare infrastructure, skilled professionals, and integrated oncology care services. Hospitals are the primary providers of SBRT treatments due to their ability to support complex procedures and manage high patient volumes.

The cancer treatment centers segment is expected to witness the fastest growth during the forecast period, fueled by increasing specialization in oncology care and rising patient preference for dedicated cancer facilities. These centers offer focused treatment approaches, advanced equipment, and improved patient management, contributing to their growing adoption globally. Expanding private investments and increasing establishment of specialized oncology centers are further accelerating segment growth.

• By Component

On the basis of component, the global SBRT market is segmented into systems, software, and services. The systems segment accounted for the largest revenue share in 2025, driven by the high cost of radiotherapy equipment such as linear accelerators, robotic radiosurgery systems, and proton therapy systems. Increasing investments in upgrading radiotherapy infrastructure and expanding treatment capabilities are supporting segment dominance.

The software segment is expected to witness the fastest growth during the forecast period, fueled by rising adoption of AI-based treatment planning systems, real-time imaging integration, and adaptive radiotherapy solutions. Software plays a critical role in enhancing treatment precision, workflow efficiency, and clinical outcomes, making it a key growth area within the SBRT market. Additionally, increasing demand for automation and data-driven decision-making in oncology is further accelerating segment growth globally.

Stereotactic Body Radiation Therapy (SBRT) Market Regional Analysis

• North America dominated the stereotactic body radiation therapy (SBRT) market with the largest revenue share of approximately 38.2% in 2025, supported by advanced healthcare infrastructure, high adoption of innovative radiotherapy technologies, and strong presence of leading market players. Countries such as the United States and Canada lead the region due to increasing cancer prevalence, favorable reimbursement frameworks, and continuous investments in oncology treatment facilities. The region’s strong focus on precision medicine and early adoption of advanced treatment modalities is further strengthening market dominance.
• Healthcare providers and oncology centers in North America place significant emphasis on improving treatment outcomes through the adoption of high-precision radiotherapy solutions, leading to widespread utilization of SBRT across various cancer types including lung, prostate, and liver cancer.
• This strong market position is further supported by increasing research and development activities, rapid technological advancements in radiotherapy systems, and growing demand for non-invasive cancer treatment options, establishing SBRT as a critical component in modern oncology care across the region.

U.S. Stereotactic Body Radiation Therapy (SBRT) Market Insight

The U.S. stereotactic body radiation therapy (SBRT) market captured the largest revenue share of approximately 79.1% within North America in 2025, driven by high adoption of advanced radiotherapy systems and strong healthcare expenditure. Healthcare providers increasingly prioritize SBRT solutions to enhance treatment precision and reduce treatment duration, particularly in the management of lung and prostate cancers. The presence of major industry players and continuous technological innovations significantly contribute to sustained market growth.

Europe Stereotactic Body Radiation Therapy (SBRT) Market Insight

The Europe stereotactic body radiation therapy (SBRT) market is projected to expand at a steady CAGR throughout the forecast period, primarily driven by increasing adoption of advanced cancer treatment technologies and strong regulatory support for healthcare innovation. Countries such as Germany, the U.K., and France are leading adoption due to well-established healthcare systems and growing focus on improving cancer treatment outcomes. Increasing investments in radiotherapy infrastructure and rising demand for minimally invasive treatments are further supporting regional growth.

U.K. Stereotactic Body Radiation Therapy (SBRT) Market Insight

The U.K. stereotactic body radiation therapy (SBRT) market is anticipated to grow at a notable CAGR during the forecast period, supported by increasing demand for advanced cancer care and strong government initiatives aimed at improving oncology services. Rising awareness regarding early cancer diagnosis and treatment, along with the expansion of radiotherapy centers, is driving adoption. The country’s focus on integrating advanced technologies into healthcare systems is further enhancing market growth.

Germany Stereotactic Body Radiation Therapy (SBRT) Market Insight

The Germany stereotactic body radiation therapy (SBRT) market is expected to expand at a considerable CAGR during the forecast period, driven by strong demand for high-quality healthcare services and leadership in medical technology innovation. The country’s emphasis on precision medicine and advanced radiotherapy solutions is supporting widespread adoption of SBRT systems. Increasing investments in research, along with strong industrial and healthcare infrastructure, are further accelerating market growth..

Asia-Pacific Stereotactic Body Radiation Therapy (SBRT) Market Insight

The Asia-Pacific stereotactic body radiation therapy (SBRT) market is poised to grow at the fastest CAGR during the forecast period of 2026 to 2033, driven by rising cancer incidence, expanding healthcare infrastructure, and increasing investments in oncology treatment facilities. Countries such as China, India, and Japan play a key role in both demand and adoption of advanced radiotherapy systems. Rising disposable income, improving access to healthcare services, and growing awareness regarding advanced cancer treatment options are accelerating adoption across the region. In addition, government initiatives aimed at strengthening cancer care infrastructure and increasing availability of radiotherapy equipment are further supporting market growth.

Japan Stereotactic Body Radiation Therapy (SBRT) Market Insight

The Japan stereotactic body radiation therapy (SBRT) market is gaining momentum due to increasing focus on advanced medical technologies and high-quality cancer care. Strong emphasis on precision treatment and early adoption of innovative radiotherapy systems is driving demand. Integration of advanced imaging technologies and continuous technological innovation are enhancing treatment efficiency and expanding application scope across oncology practices.

India Stereotactic Body Radiation Therapy (SBRT) Market Insight

The India stereotactic body radiation therapy (SBRT) market accounted for a significant revenue share in Asia-Pacific in 2025, attributed to rising cancer burden, expanding healthcare infrastructure, and increasing investments in oncology care. Growing awareness regarding advanced radiotherapy techniques and increasing availability of specialized cancer treatment centers are driving adoption. Government initiatives to improve cancer care accessibility and rising private sector investments are key factors supporting sustained market expansion in India.

Stereotactic Body Radiation Therapy (SBRT) Market Share

The Stereotactic Body Radiation Therapy (SBRT) industry is primarily led by well-established companies, including:

• BASF SE (Germany)
• Dow Inc. (U.S.)
• Evonik Industries AG (Germany)
• Arkema S.A. (France)
• Clariant AG (Switzerland)
• LANXESS AG (Germany)
• Solvay S.A. (Belgium)
• LyondellBasell Industries N.V. (Netherlands)
• Avient Corporation (U.S.)
• Croda International Plc (U.K.)
• ADEKA Corporation (Japan)
• Songwon Industrial Co. Ltd. (South Korea)
• Nouryon (Netherlands)
• Emery Oleochemicals (Malaysia)
• Cargill Incorporated (U.S.)
• Corbion N.V. (Netherlands)
• NatureWorks LLC (U.S.)
• Braskem S.A. (Brazil)
• Novamont S.p.A. (Italy)
• Palsgaard A/S (Denmark)

What are the Recent Developments in Global Stereotactic Body Radiation Therapy (SBRT) Market?

• In January 2026, Varian Medical Systems (Siemens Healthineers) expanded its stereotactic body radiation therapy (SBRT) portfolio by introducing an AI-enabled radiotherapy platform designed to enhance treatment precision, automate workflow processes, and improve patient outcomes through advanced imaging and adaptive treatment planning capabilities
• In November 2025, Elekta AB strengthened its stereotactic body radiation therapy (SBRT) solutions by launching a next-generation linear accelerator integrated with real-time adaptive radiotherapy technology, aimed at improving tumor targeting accuracy and reducing treatment time
• In September 2025, Accuray Incorporated enhanced its stereotactic body radiation therapy (SBRT) portfolio by upgrading its CyberKnife system with advanced motion tracking and Synchrony technology, enabling precise radiation delivery for moving tumors and improving clinical efficiency
• In July 2025, ViewRay Technologies, Inc. expanded its stereotactic body radiation therapy (SBRT) offerings by introducing advanced MRI-guided radiotherapy capabilities designed to improve soft tissue visualization and enable real-time treatment adaptation
• In May 2025, Ion Beam Applications S.A. strengthened its stereotactic body radiation therapy (SBRT) portfolio by advancing its proton therapy solutions aimed at delivering highly targeted radiation with reduced exposure to surrounding healthy tissues
• In March 2025, RaySearch Laboratories AB enhanced its stereotactic body radiation therapy (SBRT) software solutions by launching advanced treatment planning systems integrated with AI-based optimization tools to improve treatment accuracy and workflow efficiency
• In January 2025, Brainlab AG expanded its stereotactic body radiation therapy (SBRT) portfolio by introducing advanced image-guided navigation and treatment planning technologies aimed at improving precision in complex tumor cases
• In October 2024, GE HealthCare strengthened its stereotactic body radiation therapy (SBRT) capabilities by developing advanced imaging solutions designed to support accurate tumor localization and enhance radiotherapy treatment planning

SKU-76207